{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:12:01Z","timestamp":1785503521452,"version":"3.56.0"},"reference-count":64,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14760584.2026.2708203","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:44:04Z","timestamp":1785501844000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Modeling the public health impact of vaccination with Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025\u20132026 formula in the pediatric population aged 5\u201317\u2009years at high risk of severe outcomes from COVID-19 in the United States"],"prefix":"10.1080","volume":"25","author":[{"given":"Alon","family":"Yehoshua","sequence":"first","affiliation":[{"name":"Value and Evidence, Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Di Fusco","sequence":"additional","affiliation":[{"name":"Value and Evidence, Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby E.","family":"Rudolph","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thoburn","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago M.C.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Dodd","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Yarnoff","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"Centers for Disease Control and Prevention. Preliminary estimates of COVID-19 burden for 2024\u20132025 [Internet]. 2024 [cited 2025 Mar 19]. Available from: https:\/\/www.cdc.gov\/covid\/php\/surveillance\/burden-estimates.html\/0"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-072788"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6932e3"},{"key":"e_1_3_5_5_1","unstructured":"National Center for Immunization and Respiratory Diseases. Advisory committee on Immunization practices (ACIP) meeting: COVID-19\u2013associated hospitalizations - COVID-NET April 2025. 2025 [2025 Sep 22]. Available from: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/03-Havers-COVID-508.pdf"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2193067"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00100-3"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060894"},{"key":"e_1_3_5_9_1","unstructured":"National Center for Immunization and Respiratory Diseases. Advisory committee on Immunization practices: updates to COVID-19 vaccine effectiveness 2025. 2025. Available from: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-09-18-19\/04-Srinivasan-covid-508.pdf"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117995"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7440a1"},{"key":"e_1_3_5_12_1","unstructured":"Centers for Disease and Control Prevention. COVID data tracker: variant proportions 2023. 2023. Available from: https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.01.024"},{"key":"e_1_3_5_14_1","volume-title":"Updated COVID-19 vaccines for use in the United States Beginning in Fall 2024","author":"FDA","year":"2024","unstructured":"FDA. Updated COVID-19 vaccines for use in the United States Beginning in Fall 2024. Silver Spring, MD, USA: U.S. Food and Drug Administration (FDA); 2024."},{"key":"e_1_3_5_15_1","unstructured":"FDA. COVID-19 vaccines (2025\u20132026 formula) for use in the United States Beginning in Fall 2025. 2025 [cited 2025 May 22]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/industry-biologics\/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025?utm_source=chatgpt.com\/1"},{"key":"e_1_3_5_16_1","unstructured":"Pfizer and BioNTech\u2019s Comirnaty receives U.S. FDA approval for adults 65 and older and individuals ages 5 through 64 at increased risk for severe COVID-19 [Internet]. 2025; Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontechs-comirnatyr-receives-us-fda-approval"},{"key":"e_1_3_5_17_1","unstructured":"Food and Drug Administration. Comirnaty (COVID-19 vaccine (RNA) suspension for injection for intramuscular use. 2025. Available from: https:\/\/www.fda.gov\/media\/151707\/download"},{"key":"e_1_3_5_18_1","unstructured":"Centers for Disease and Control Prevention. Child immunization schedule notes 2025. 2025. Available from: https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/child-adolescent-notes.html#note-covid-19"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2025.114778"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49944"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2071427"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2429335"},{"key":"e_1_3_5_23_1","unstructured":"Centers for Disease Control and Prevention. Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity. 2021 [cited 2022 Feb 16]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/vaccine-induced-immunity.html"},{"key":"e_1_3_5_24_1","unstructured":"Jarvis L. Covid boosters like flu shots need a yearly schedule: Bloomberg.com. 2022 [cited 2022 Oct 30]. Available from: https:\/\/www.bloomberg.com\/opinion\/articles\/2022-06-01\/covid-boosters-like-flu-shots-need-a-yearly-schedule?leadSource=uverify%20wall"},{"key":"e_1_3_5_25_1","unstructured":"Centers for Disease Control and Prevention. Rates of COVID-19 cases or deaths by age group and updated (bivalent) booster status [Internet]. 2023 [cited 2023 Jun 1]. Available from: https:\/\/data.cdc.gov\/Public-Health-Surveillance\/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and\/54ys-qyzm\/about_data\/2"},{"key":"e_1_3_5_26_1","unstructured":"US Census Bureau. Population and housing unit estimates. Available from: https:\/\/www.census.gov\/programs-surveys\/popest.html"},{"issue":"4","key":"e_1_3_5_27_1","doi-asserted-by":"crossref","first-page":"102810","DOI":"10.1016\/j.acap.2025.102810","article-title":"Prevalence and trends in pediatric-onset chronic conditions in the United States, 1999\u20132018","volume":"25","author":"Wisk LE","year":"2025","unstructured":"Wisk LE, Sharma N. Prevalence and trends in pediatric-onset chronic conditions in the United States, 1999\u20132018. Acad Pediatr. 2025;25(4):102810.","journal-title":"Acad Pediatr"},{"key":"e_1_3_5_28_1","unstructured":"Centers for Disease Control and Prevention (CDC). Rates of COVID-19 cases or deaths by age group and updated (bivalent) booster status. 2023 Available from: https:\/\/data.cdc.gov\/Public-Health-Surveillance\/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and\/54ys-qyzm\/about_data\/3"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2811.221109"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25320"},{"key":"e_1_3_5_31_1","unstructured":"Centers for Disease Control and Prevention. About reinfection [Internet]. 2024. Available from: https:\/\/www.cdc.gov\/covid\/about\/reinfection.html"},{"key":"e_1_3_5_32_1","volume-title":"COVID-19 vaccine doses administered by manufacturer, United States, Sept 2022 - March 2023","author":"Our World in Data","year":"2024","unstructured":"Our World in Data. COVID-19 vaccine doses administered by manufacturer, United States, Sept 2022 - March 2023. Oxford, UK: Our World in Data; 2024."},{"key":"e_1_3_5_33_1","unstructured":"Centers for Disease and Control Prevention. COVID-19 vaccination coverage and intent for vaccination children 6 months through 17 years United States. 2025. Available from: https:\/\/www.cdc.gov\/covidvaxview\/weekly-dashboard\/child-coverage-vaccination.html"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.0750"},{"key":"e_1_3_5_35_1","unstructured":"Klein NP Shimabukuro T. Safety update of 1st booster mRNA COVID-19 vaccination 2022. 2022. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/116526"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0600"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.7179"},{"key":"e_1_3_5_38_1","unstructured":"Centers for Disease Control and Prevention. COVID-NET laboratory-confirmed COVID-19\u00a0hospitalizations 2024\u20132025 [Internet]. 2026. Available from: https:\/\/covid.cdc.gov\/covid-data-tracker\/#covidnet-hospitalization-network"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2416873"},{"key":"e_1_3_5_40_1","unstructured":"Centers for Disease Control and Prevention. Long COVID basics 2024. 2024. Available from: https:\/\/www.cdc.gov\/covid\/long-term-effects\/index.html"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7232a2"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.23253"},{"key":"e_1_3_5_43_1","unstructured":"CDC. Underlying conditions and the higher risk for severe COVID-19 2025. 2025. Available from: https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html"},{"key":"e_1_3_5_44_1","unstructured":"CDC recommends updated 2024\u20132025 COVID-19 and flu vaccines for fall\/winter virus season [Internet]. 2024. Available from: https:\/\/www.cdc.gov\/media\/releases\/2024\/s-t0627-vaccine-recommendations.html"},{"key":"e_1_3_5_45_1","unstructured":"Food and Drug Administration. COVID-19 vaccines (2025\u20132026 formula) for use in the United States beginning in Fall 2025. 2025. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/industry-biologics\/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025?utm_source=chatgpt.com\/4"},{"key":"e_1_3_5_46_1","unstructured":"Centers for Disease Control and Prevention (CDC). Reinfections and COVID-19. 2022 [cited 2022 Oct 30]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/your-health\/reinfection.html"},{"key":"e_1_3_5_47_1","unstructured":"Pfizer. Comirnaty label. 2023."},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454579"},{"issue":"15","key":"e_1_3_5_49_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.15585\/mmwr.mm7315a2","article-title":"Durability of original monovalent mRNA vaccine effectiveness against COVID-19 omicron-associated hospitalization in children and adolescents - United States, 2021\u20132023","volume":"73","author":"Zambrano LD","year":"2024","unstructured":"Zambrano LD, Newhams MM, Simeone RM, et al. Durability of original monovalent mRNA vaccine effectiveness against COVID-19 omicron-associated hospitalization in children and adolescents - United States, 2021\u20132023. MMWR Morb Mortal Wkly Rep. 2024;73(15):330\u2013338.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102962"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.59672"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.27022"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.13586"},{"key":"e_1_3_5_54_1","unstructured":"Link-Gelles R. Effectiveness of COVID-19 (2023\u20132024 formula) vaccines. 2024."},{"key":"e_1_3_5_55_1","unstructured":"Link-Gelles R. Interim estimates of 2024\u20132025 COVID-19 vaccine effectiveness. 2025."},{"key":"e_1_3_5_56_1","unstructured":"Centers for Disease and Control Prevention. Weekly flu vaccination dashboard 2025. 2026. Available from: https:\/\/www.cdc.gov\/fluvaxview\/dashboard\/index.html#:~:text=respondent%20self%2Dreport.- Data%20and%20charts%20are%20available.definitely%20will%20get%20a%20vaccine"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13020115"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.11.040"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.046"},{"key":"e_1_3_5_60_1","unstructured":"Control CfD Prevention. Preliminary estimates of COVID-19 burden: Centers for Disease Control and Prevention. 2026 [cited 2026 Feb 6]. Available from: https:\/\/www.cdc.gov\/covid\/php\/surveillance\/burden-estimates.html\/5"},{"key":"e_1_3_5_61_1","unstructured":"Control CfD Prevention. Estimated US flu disease burden: Centers for disease Control and Prevention. 2026 [cited 2026 Mar 6]. Available from: https:\/\/www.cdc.gov\/flu-burden\/php\/data-vis\/index.html"},{"issue":"9","key":"e_1_3_5_62_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.15585\/mmwr.mm7509a2","article-title":"Interim estimates of 2025\u201326 seasonal influenza vaccine effectiveness - United States, September 2025-February 2026","volume":"75","author":"Maloney P","year":"2026","unstructured":"Maloney P, Reeves EL, Wielgosz K, et al. Interim estimates of 2025\u201326 seasonal influenza vaccine effectiveness - United States, September 2025-February 2026. MMWR Morb Mortal Wkly Rep. 2026;75(9):116\u2013123.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology11020190"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/rsp3.12372"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.07.002"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2708203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14760584.2026.2708203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2708203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:44:09Z","timestamp":1785501849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2026.2708203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14760584.2026.2708203"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2026.2708203","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2708203"}}